Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2010 | 1 |
2011 | 1 |
2019 | 1 |
2021 | 1 |
2022 | 2 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Quoted phrase not found in phrase index: "Grade 4 Gastritis, CTCAE"
Page 1
Clinical Characteristics and Outcomes of Gastritis Associated With Immune Checkpoint Inhibitors: Scoping Review.
J Immunother. 2022 Oct 1;45(8):363-369. doi: 10.1097/CJI.0000000000000435. Epub 2022 Aug 16.
J Immunother. 2022.
PMID: 35972801
Review.
Twenty-two articles, including 5 observational studies and 17 case reports and case series, were included. Nivolumab, pembrolizumab, and combination therapy with those and cytotoxic T-lymphocyte-associated antigen-4 inhibitor (ipilimumab) were commonly used in those …
Twenty-two articles, including 5 observational studies and 17 case reports and case series, were included. Nivolumab, pembrolizumab, …
Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer.
Liermann J, Ben-Josef E, Syed M, Debus J, Herfarth K, Naumann P.
Liermann J, et al.
Strahlenther Onkol. 2022 Apr;198(4):378-387. doi: 10.1007/s00066-021-01827-9. Epub 2021 Aug 5.
Strahlenther Onkol. 2022.
PMID: 34351449
Free PMC article.
During radiotherapy, we registered one gastrointestinal bleeding CTCAE grade III (8%) due to gastritis. The bleeding was sufficiently managed with conservative therapy. No further higher-grade acute or late toxicities were observed. CONCLUSION: …
During radiotherapy, we registered one gastrointestinal bleeding CTCAE grade III (8%) due to gastritis. The bleeding wa …
Item in Clipboard
Yttrium-90 trans-arterial radioembolization in advanced-stage HCC: The impact of portal vein thrombosis on survival.
Somma F, Stoia V, Serra N, D'Angelo R, Gatta G, Fiore F.
Somma F, et al.
PLoS One. 2019 May 29;14(5):e0216935. doi: 10.1371/journal.pone.0216935. eCollection 2019.
PLoS One. 2019.
PMID: 31141552
Free PMC article.
RESULTS: The average activity administered was 1.7 0.4 GBq. After the treatment, CTCAE grade 2 adverse events occurred in 46% (41/89) patients: in particular, fever and abdominal pain were found in 25 and 16 patients, respectively. No major side-effect was …
RESULTS: The average activity administered was 1.7 0.4 GBq. After the treatment, CTCAE grade 2 adverse events occurred …
Item in Clipboard
Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors.
Chon YE, Seong J, Kim BK, Cha J, Kim SU, Park JY, Ahn SH, Han KH, Chon CY, Shin SK, Kim DY.
Chon YE, et al.
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1343-51. doi: 10.1016/j.ijrobp.2010.07.1986. Epub 2010 Oct 8.
Int J Radiat Oncol Biol Phys. 2011.
PMID: 20934268
Radiation-induced gastroduodenal complications were defined as radiation gastritis/duodenitis, radiation gastric/duodenal ulcer, or other gastroduodenal toxicity associated with radiation, based on Common Terminology Criteria for Adverse Events (CTCAE 3.0). Serious …
Radiation-induced gastroduodenal complications were defined as radiation gastritis/duodenitis, radiation gastric/duodenal ulcer, or o …
Item in Clipboard
Cite
Cite